88356940
Mar 26, 2019
Pharmaceutical preparations, namely, nonsteroidal anti-inflammatory drugs (NSAIDs), ibuprofen, naproxen sodium, acetaminophen, cold, sore throat and cough medications, guaifenesin, liquid cough medicines with dextromethorphan, decongestant nasal sprays, pseudoephedrine, phenylephrine, allergy medications, antihistamine pills and liquids, diphenhydramine, chlorpheniramine, brompheniramine, loratadine, fexofenadine, cetirizine, stomach upset medications, antidiarrhea medicines, loperamide, bismuth, nausea and vomiting, motion sickness, dimenhydrinate; cannabidiol (CBD) which is synthetically derived with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis for medical purposes; cannabidiol (CBD) which is synthetically derived with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis for treating, reducing or improving symptoms of various conditions, namely, pain, anxiety, depression, cancer, acne, skin conditions, neuroprotection, cardiovascular health, arthritis, inflammation, autoimmune conditions, epileptic seizures, nausea, appetite, inflammatory bowel disease, and insomnia; cannabidiol (CBD) which is synthetically derived with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis for medical purposes in sublingual doses and mucous membrane doses; skin creams, ointments, tablets, capsules, gummies, suppositories, skin patches, extended release tablets and liquids for therapeutic purposes containing cannabidiol (CBD) which is synthetically derived with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis; herbal supplements containing cannabidiol (CBD) which is synthetically derived with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis; Liquid nutritional supplements containing cannabidiol (CBD) which is synthetically derived with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis for treating, reducing or improving symptoms of various conditions, namely, pain, anxiety, depression, cancer, acne, skin conditions, neuroprotection, cardiovascular health, arthritis, inflammation, autoimmune conditions, epileptic seizures, nausea, appetite, inflammatory bowel disease, and insomnia
Pharmaceuticals